Printed From BioPortfolio.com
Bristol-Myers Squibb Brings Out Its Ace Card In The Midst Of An IDO Inhibitor Battle
11:34 EST 13 Nov 2017 | Topix
Bristol-Myers Squibb released positive results in an early-stage study using an IDO inhibitor drug in combination with Opdivo in both bladder and cervical cancer patients. Recently, Bristol-Myers Squibb revealed data from its own IDO inhibitor drug in combination with Opdivo which was quite stellar.
Original Article: Bristol-Myers Squibb Brings Out Its Ace Card In The Midst Of An IDO Inhibitor Battle
